Stroke Thrombectomy and Aneurysm Registry
Recruiting
This international multi-center registry is used to collect existing information and outcomes for patients undergoing an operation for treatment of injuries to the brain including the blockage of blood flow to an area of the brain, an abnormal ballooning of an artery, abnormal tangling of blood vessels, abnormal formation of blood vessels, tearing of vein, and bleeding in the brain. This information is used to help predict outcomes that undergo an operation for treatment of the above-listed brai... Read More
Gender:
All
Ages:
Between 1 year and 120 years
Trial Updated:
11/30/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Stroke, Thromboses, Intracranial, Aneurysm, Brain
ET-01 in Subjects With Lateral Canthal Lines, LCL-210
Recruiting
This study tests an investigational drug formulation called ET-01, botulinum toxin, Type A, topical, in lateral canthal lines (LCL).
Gender:
All
Ages:
Between 25 years and 65 years
Trial Updated:
11/30/2023
Locations: Eirion Research Site, Greenville, South Carolina
Conditions: Lateral Canthal Lines, LCL, Crow's Feet
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
Recruiting
This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
Gender:
All
Ages:
1 year and below
Trial Updated:
11/30/2023
Locations: Tribe Clinical Research, LLC ( Site 0002), Greenville, South Carolina
Conditions: RSV Infection
Oral Omadacycline vs. Placebo in Adults With NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
Recruiting
The purpose of this study is to evaluate the efficacy, safety and tolerability of oral omadacycline as compared to placebo in the treatment of adults with Nontuberculous Mycobacterial (NTM) pulmonary disease caused by Mycobacterium abscessus complex (MABc)
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Medical University of South Carolina (MUSC), Charleston, South Carolina
Conditions: Mycobacterium Infections, Nontuberculous, Mycobacterium Abscessus Infection, Nontuberculous Mycobacterial Lung Disease, Nontuberculous Mycobacterial Pulmonary Infection
A Study to Evaluate EDP 938 Regimens in Children With RSV
Recruiting
A 2-part study to evaluate the safety, pharmacokinetics and efficacy of EDP-938 in children with RSV infection.
Gender:
All
Ages:
Between 28 days and 36 months
Trial Updated:
11/30/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Respiratory Syncytial Virus (RSV)
A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)
Recruiting
The purpose of this study is to assess the safety, tolerability, and efficacy of BMS-986158 alone and in combination with either Ruxolitinib or Fedratinib in participants with Dynamic International Prognostic Scoring System (DIPSS)-intermediate or high risk blood cancer. Part 1 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and Part 2 consists of BMS-986158 in combination with either Ruxolitinib or Fedratinib and BMS-986158 alone.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Medical University of South Carolina, Charleston, South Carolina
Conditions: Myelofibrosis
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
Recruiting
The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced cc... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Ralph H. Johnson VA Center ( Site 0073), Charleston, South Carolina
Conditions: Carcinoma, Renal Cell
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
Recruiting
The purpose of this study is to compare overall survival (OS) and progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR). Hypothesis (H1): Concurrent chemoradiation therapy with pembrolizumab followed by pembrolizumab plus olaparib is superior to concurrent chemoradiation therapy alone with respect to PFS per RECIST 1.1 by BICR. Hypothesis (H2): Concurrent chemoradiation therapy with pem... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Saint Francis Cancer Center ( Site 0087), Greenville, South Carolina
Conditions: Small Cell Lung Cancer
Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)
Recruiting
Tomivosertib combined with pembrolizumab in Subjects with PD-L1 positive NSCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Prisma Health Cancer Institute, Greenville, South Carolina
Conditions: Non-small Cell Lung Cancer
Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)
Recruiting
This is a variable length study to evaluate the efficacy and safety of budesonide/glycopyrronium/formoterol inhaler in adults and adolescents with severe asthma inadequately controlled with standard of care
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
11/30/2023
Locations: Research Site, Anderson, South Carolina
Conditions: Asthma
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)
Recruiting
A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
11/30/2023
Locations: Premier Neurology, Greenville, South Carolina
Conditions: Relapsing Multiple Sclerosis
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
Recruiting
This phase III trial studies how well atezolizumab added to the usual radiation therapy works in treating patients with stage I-IIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high pr... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/30/2023
Locations: Saint Joseph's/Candler - Bluffton Campus, Bluffton, South Carolina
Conditions: Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8